Oruka Therapeutics appoints Christopher Martin to board; Cameron Turtle resigns

Oruka Therapeutics, Inc.

Cameron Turtle resigned as director on Dec 11, 2025; not due to disagreement with the company.
Christopher Martin appointed as Class II director, Chair of Compensation Committee, and Audit Committee member.
Martin previously Chief Commercial Officer at Verona Pharma, acquired by Merck for ~$10B in Oct 2025.
He received an option to buy 35,000 shares vesting over 3 years; annual cash retainers: $40K (board), $12K (Comp Chair), $7.5K (Audit).
Martin also serves on the board of Edgewise Therapeutics (EWTX).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.